Royalty Pharma Declares Third Quarter 2024 Dividend

Group 1 - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical industry [1] - The company collaborates with various entities, including academic institutions, research hospitals, non-profits, small and mid-cap biotechnology companies, and leading global pharmaceutical companies [1] - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 17 development-stage product candidates, featuring notable therapies such as Vertex's Trikafta and GSK's Trelegy [1] Group 2 - The board of directors of Royalty Pharma has approved a dividend of $0.21 per Class A ordinary share for the third quarter of 2024 [2] - The dividend payment is scheduled for September 13, 2024, to shareholders of record as of August 16, 2024 [4]